Drug companies raised prices on seven popular drugs during 2017 and 2018 without clinical evidence that the drugs had been improved in any way, according to a new report.
The increases cost patients and insurers more than $5 billion, the Institute for Clinical and Economic Review (ICER) found in its report. None of the drugs examined showed evidence of improved safety or effectiveness, the analysis found.
The report looked at the seven top-selling drugs by sales revenue that had price increases of more than two times inflation, as measured by the medical consumer price index.
The culprits, and how much they added to drug spending over two years:
- Humira: $1.9 billion
- Rituxan: $806 million
- Lyrica: $688 million
- Truvada: $550 million
- Neulasta: $489 million
- Cialis: $403 million
- Tecfidera: $313 million